# Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

> **NCT00394810** · PHASE2 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Panzem® NCD

## Key facts

- **NCT ID:** NCT00394810
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2008-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394810, "Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00394810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*